-- Unknown to Most Americans --

Most Americans have no idea that some of the drugs they are buying from Canadian Pharmacies are produced and outsourced to an Indian pharmacy.

Beginning January 1, 2006, the entire drug importation issue changed dramatically with the implementation of Medicare Part D by Congress.

Talk of Canadian imports all but disappeared from the media. Within 9 months of the creation of Medicare's new drug program, Wal-Mart announced that it would

begin selling in the Tampa, Florida trade area, a month's supply from a list of 150 generic drugs for $4 each. By the end of April of 2007, Wal-Mart was "in advanced

talks" with the largest Indian pharmaceutical exporting companies like Ranbaxy, Dr. Reddy's Labs, Cipla, Lupin and Sun Pharma.

 

Overseas Pharmacy Guide

List online Indian pharmacies that get the exact same drugs from these Indian manufacturers they are the largest Indian

pharmaceutical exporting companies like Ranbaxy, Dr. Reddy's Labs, Cipla, Lupin and Sun Pharma.

 

For instance if you were to buy Generic Viagra from Generic Pharmacy they use Ranbaxy.

Ranbaxy Launch Website Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographic. The Company is ranked amongst the top ten global generic companies and has a presence in 23 of the top 25 pharma markets of the world. Top

---

Wal-Mart is now buying drugs directly from Indian pharmaceutical manufacturers.

One industry analyst says that Wal-Mart's drugs "come from all over the world. They have a choice of where to buy these drugs. That's part of the reason why they're

able to price them at this low price point. In 2005, Ranbaxy won Wal-Mart's Supplier Award for outstanding performance. Ranbaxy expects that its

U.S. division, largely buoyed by Wal-Mart, will bring in 50% of the corporation's revenues.

The Indian drug company's sales in the U.S. increased ten-fold from 1999 to 2003.

The companies were taking advantage of India's low labor costs and highly-skilled work force to expand outside their home base. Ranbaxy had challenged the

patents on blockbuster drugs such as Pfizer's Lipitor and AstraZeneca's Nexium.